118 related articles for article (PubMed ID: 38161136)
21. Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).
Wu JJ; Lee PH; Zheng ZR; Huang YH; Tseng JS; Hsu KH; Yang TY; Yu SL; Chen KC; Chang GC
Medicine (Baltimore); 2022 Jun; 101(24):e29381. PubMed ID: 35713442
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
23. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
24. Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Murugesan K; Jin DX; Comment LA; Fabrizio D; Hegde PS; Elvin JA; Alexander B; Levy MA; Frampton GM; Montesion M; Roychowdhury S; Kurzrock R; Ross JS; Albacker LA; Huang RSP
Oncologist; 2022 Sep; 27(9):732-739. PubMed ID: 35598202
[TBL] [Abstract][Full Text] [Related]
25. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
[TBL] [Abstract][Full Text] [Related]
27. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
Front Immunol; 2022; 13():931718. PubMed ID: 35990690
[TBL] [Abstract][Full Text] [Related]
28. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
29. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
[TBL] [Abstract][Full Text] [Related]
30. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
31. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With
Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y
JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645
[TBL] [Abstract][Full Text] [Related]
33. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
34. Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China.
Wang Y; Lu J; Wu C; Fei F; Chu Z; Lu P
Front Immunol; 2023; 14():1276107. PubMed ID: 38124739
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
36. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Jung EH; Jang HR; Kim SH; Suh KJ; Kim YJ; Lee JH; Chung JH; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
38. Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients.
Heo JY; Yoo SH; Suh KJ; Kim SH; Kim YJ; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Sci Rep; 2021 Jan; 11(1):2514. PubMed ID: 33510255
[TBL] [Abstract][Full Text] [Related]
39. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
[TBL] [Abstract][Full Text] [Related]
40. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]